We are live on ! Find out more
SBFM

Sunshine Biopharma
SBFM

11 hedge funds and large institutions have $337K invested in Sunshine Biopharma in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

80% more capital invested

Capital invested by funds: $187K → $337K (+$150K)

22% more funds holding

Funds holding: 9 → 11 (+2)

0.21% more ownership

Funds ownership: 0.29% → 0.5% (+0.21%)

Holders
11
Holders Change
+2
Holders Change %
+22.22%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
+$66.7K
2
Two Sigma Investments
Two Sigma Investments
New York
+$31.7K
3
TSS
Two Sigma Securities
New York
+$25.5K
4
Citadel Advisors
Citadel Advisors
Florida
+$21.7K
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.39K

Top Sellers

Rank Fund Capital Flow
1
SS
SBI Securities
Japan
-$2.73K
2
SM
Sabby Management
Florida
-$2.24K

SBFM Hedge Fund Activity: Q3 2025 in Review

11 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q3 2025, worth a combined $337K — up 80% from $187K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new SBFM positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was DRW Securities, opening a new position worth an estimated $66.7K. The largest seller was SBI Securities, cutting an estimated $2.73K.

  • 11 institutional investors held Sunshine Biopharma (SBFM) as of Q3 2025, up from 9 in Q2 2025.
  • Funds reported $337K of Sunshine Biopharma stock for Q3 2025, up 80% quarter-over-quarter.
  • 3 funds opened new Sunshine Biopharma positions in Q3 2025 and 1 closed out, a net change of +2 holders.
  • The largest Sunshine Biopharma buyer in Q3 2025 was DRW Securities, an estimated $66.7K added.
  • The largest Sunshine Biopharma seller in Q3 2025 was SBI Securities, an estimated $2.73K sold.

Based on aggregated 13F filings for Q3 2025.